Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.
Department of Animal Physiology and Immunology, School of Life Sciences, Technical University Munich, D-85354 Freising, Germany.
Int J Oncol. 2022 Nov;61(5). doi: 10.3892/ijo.2022.5423. Epub 2022 Sep 21.
Extracellular vesicles (EVs) have recently come into the spotlight as potential cancer biomarkers. Isolation of pure EVs is complex, so wider use requires reliable and time‑efficient isolation methods. In the present study, galectin‑based magnetic glycan recognition particles, EXÖBead were investigated for their practicality as a novel EV isolation technique, exemplified here for squamous cell carcinoma of the head and neck. Analysis of the isolation method showed a high concentration of pure EVs with detection of specific EV markers such as CD9, CD63, CD81 and TSG101. No apolipoprotein A1 was shown in the isolates, indicating low contamination of this isolation technique compared with size exclusion chromatography. In addition, common leukocyte antigen (CD45), three HNSCC [epithelial cell adhesion molecule (EpCAM), pan‑cytokeratin and programmed death‑ligand 1 (PD‑L1)] and PanEV markers (premixed CD9, CD63 and CD81 antibodies) were measured by bead‑based flow cytometry (BFC). BFC revealed that CD45 PanEV, EpCAM PanEV and PD‑L1 PanEV were significantly higher in tumor patients compared with healthy control plasma. CD45 PanEV and CD45 PanEV carrying two or three HNSCC biomarkers were also significantly higher in tumor patients compared with healthy controls (BFC). Comparison of the functional immunosuppression effect of eluted tumor patient plasma EVs from EXÖBead and commercial polyethylene glycol isolation showed a significant tumor‑dependent increase in concentration of EVs. A peripheral blood mononuclear cell activation assay also showed that the T‑cell functionality of tumor patient plasma EVs isolated with EXÖBead was preserved . In conclusion, isolation using galectin‑based magnetic glycan recognition particles is a novel method for isolating plasma EVs with low lipoprotein contamination. Bead‑based flow cytometry provided an easy way to understand EV subpopulations. EXÖBead therefore showed great potential as a new isolation tool with high throughput capacity that could potentially be used in a clinical setting.
细胞外囊泡 (EVs) 最近成为癌症生物标志物的研究热点。由于 EV 的分离较为复杂,因此需要可靠且高效的分离方法来广泛应用。本研究中,我们研究了基于半乳糖凝集素的磁性糖识别颗粒 EXÖBead 作为一种新型 EV 分离技术的实用性,在此以头颈部鳞状细胞癌为例进行了说明。该分离方法的分析表明,可以获得高浓度的纯 EV,并检测到特定的 EV 标志物,如 CD9、CD63、CD81 和 TSG101。在分离物中未检测到载脂蛋白 A1,表明与尺寸排阻色谱相比,该分离技术的污染程度较低。此外,通过基于珠子的流式细胞术 (BFC) 测量了常见白细胞抗原 (CD45)、三种 HNSCC [上皮细胞黏附分子 (EpCAM)、泛细胞角蛋白和程序性死亡配体 1 (PD-L1)] 和 PanEV 标志物(预混合的 CD9、CD63 和 CD81 抗体)。BFC 结果显示,与健康对照血浆相比,肿瘤患者的 CD45 PanEV、EpCAM PanEV 和 PD-L1 PanEV 明显更高。与健康对照相比,肿瘤患者的 CD45 PanEV 和携带两种或三种 HNSCC 标志物的 CD45 PanEV 也明显更高(BFC)。比较 EXÖBead 和商用聚乙二醇分离洗脱的肿瘤患者血浆 EV 的功能免疫抑制作用显示,EV 浓度与肿瘤依赖性显著增加。外周血单核细胞激活试验还表明,EXÖBead 分离的肿瘤患者血浆 EV 保留了 T 细胞功能。总之,基于半乳糖凝集素的磁性糖识别颗粒的分离是一种分离脂蛋白污染较少的新型血浆 EV 的方法。基于珠子的流式细胞术提供了一种简单的方法来了解 EV 亚群。因此,EXÖBead 作为一种具有高通量能力的新型分离工具具有很大的潜力,可能在临床环境中使用。